Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC

Nisa Investment Advisors LLC lowered its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 96.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 508 shares of the company’s stock after selling 15,119 shares during the period. Nisa Investment Advisors LLC’s holdings in Celcuity were worth $51,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV purchased a new stake in Celcuity during the third quarter worth about $27,000. BNP Paribas Financial Markets boosted its holdings in Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares in the last quarter. US Bancorp DE boosted its holdings in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Celcuity by 211.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in shares of Celcuity in the third quarter valued at about $79,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Insider Activity at Celcuity

In related news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the completion of the transaction, the director owned 6,760 shares of the company’s stock, valued at approximately $745,425.20. This represents a 30.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 15.78% of the company’s stock.

Celcuity Stock Performance

Shares of CELC opened at $115.56 on Wednesday. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55. The company has a market capitalization of $5.59 billion, a price-to-earnings ratio of -30.49 and a beta of 0.41. The company’s 50 day simple moving average is $109.87 and its 200 day simple moving average is $94.07. Celcuity, Inc. has a 1 year low of $7.57 and a 1 year high of $120.32.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.09. On average, sell-side analysts predict that Celcuity, Inc. will post -2.62 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CELC. Wall Street Zen raised shares of Celcuity from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Stifel Nicolaus upped their price target on shares of Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $122.00 price target on shares of Celcuity in a report on Thursday, March 26th. Wells Fargo & Company began coverage on shares of Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and an average target price of $109.88.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.